Succes stories

Our Success stories in 2017

Finished projects under fundraising process

Signed deals Sector Round size Year Investors Consulting Role
Transplant Biomedicals Medtech 150 k€ 2013 Caixa Capital Risc & BAs Interim CEO
Oxolife Nutraceuticals 5,5 M€ 2014 Ken Pharma Interim CEO
Leukos Biotech Pharma 100 k€ 2015 BAs Interim CEO
Leukos Biotech Pharma, IVD 3,5 M€ 2016 Inveready Consultant
Peptomyc Biotech 2,4 M€ 2016 Healthequity and BAs Interim CEO and Board member
AptaTargets Pharma 4,5 M€ 2017 Caixa Capital Risc, Inveready Consultant and Board member
Anaconda Biomed Medtech 15 M€ 2017 Ysios, Omega, Innogest, BSabadell Consulant and Board member
Peptomyc Biotech 4,2 M€ 2017 ALTA Life Sciences, Healthequity Consultant and Board member
GlyCardia Diagnostics IVD 3,1 M€ 2017 Caixa Capital Risc, Healthequity Consultant and Board member
MJN Neuroserveis Medtech 750 k€ 2018 Ship2B and Family Offices Consultant and Board member
Cornea Project IVD 300 k€ 2018 Industrial partner Consultant and Board member

  • Pharma project: new aptamer for ischemic stroke
  • 2,7 M€ raised in May 2017
  • Genesis consulting role: Leader
  • Investors: Caixa Capital Risc and Inveready

  • Medtech project
  • 15 M€ raised in May 2017
  • Genesis consulting role: Advisor to CEO
  • Investors: Ysios, Omega, Innogest, Banc Sabadell

  • IVD project: new biomarker for cardiovascular ischemia
  • 2,4 M€ raised in October 2017
  • Genesis consulting role: Leader
  • Investors: Caixa Capital Risc and Healthequity

  • Biotech project: recombinant protein for NSCLC and TNBC
  • 4,2 M€ raised in July 2017
  • Genesis consulting role: Leader
  • Investors: ALTA Life Sciences and Healthequity

Current projects under fundraising process

Company sector Product Indication Round size
Ophtalmology IVD Cornea disorders 3,6 M€
Cardiovascular Medtech Atrial fibrillation 4,5 M€
Nephrology IVD Renal failure 300 K€
Women’s health Pharma Fertility 4,5 M€
Gastrointestinal Medtech Chronic Constipation 2 M€